Back to Search Start Over

1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC.

Authors :
Ikeda, M.
Zhu, A.X.
Qin, S.
Kim, T-Y.
Lim, H.Y.
Kudo, M.
Breder, V.
Merle, P.
Kaseb, A.
Li, D.
Ma, N.
Villalobos, M.
Stanzel, S.
Gaillard, V.E.
Xu, D-Z.
Hernandez, S.
Cheng, A-L.
Finn, R.S.
Galle, P.R.
Ducreux, M.P.
Source :
Annals of Oncology. 2020 Supplement 4, Vol. 31, pS698-S699. 2p.
Publication Year :
2020

Subjects

Subjects :
*ATEZOLIZUMAB
*BEVACIZUMAB
*ADVERSE health care events

Details

Language :
English
ISSN :
09237534
Volume :
31
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
152695659
Full Text :
https://doi.org/10.1016/j.annonc.2020.08.1124
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details